Pharma Update

Tiragolumab development program continues to expand Continued confidence in anti-TIGIT biological activity based on numerous evidence to date First-in-class anti-TIGIT mAb Clinical development program Roche Myeloid cells Antigen Presentation PD-L1 † MHCI MHC II FOXP3 TIGIT FcR FcR C PVR CD226 Treg TIGIT Suppression Tiragolumab Atezolizumab TCF7 TOX CD8+ T cell ↑ Effector function Tumor Indication Phl Ph II Ph III Lung cancer 1L NSCLC: PD-L1 high Stage III unres. NSCLC Neoadj/Adj NSCLC 1L NSq NSCLC 1L uHCC SKYSCRAPER-01 Results in Q4/Q1 SKYSCRAPER-03 SKYSCRAPER-05 SKYSCRAPER-06 SKYSCRAPER-14/IMbrave 152 Locally advanced ESCC SKYSCRAPER-07 LPI in Q3 GI/GU cancer 1L ESCC SKYSCRAPER-08 Other solid tumors 2L+ PD-L1+ Cervical Ca 1L SCCHN SKYSCRAPER-04 Results in H1 2024 Results in H2 2023 SKYSCRAPER-09 Fixed Dose Combination SKYSCRAPER-11 Subcutaneous . Tiragolumab blocks the binding of TIGIT to its ligand PVR Tiragolumab activates T-cells and also modifies the tumor microenvironment by decreasing suppressive T-regs and activating myeloid cells via its intact Fc region Formulations Comprehensive development program ongoing Ph III SKYSCRAPER-14/IMbrave 152 in 1L unresectable HCC initiated • This could lead to an enhanced anti-tumor immune response when combined with PD-L1 blockade • Ph III SKYSCRAPER-01 continues to the final OS analysis expected in Q4/Q1 (event-driven) 72 mAb= monoclonal antibody; NSCLC-Non-Small Cell Lung Cancer; ESCC-esophageal squamous cell carcinoma; NSq=non-squamous; HCC-hepatocellular carcinoma; uHCC-unresectable hepatocellular carcinoma; SCCHN-squamous cell carcinoma of head and neck; OS-Overall survival; LPI=last patient in; PVR=Poliovirus receptor

View entire presentation